Clinical Trials
Millennium begins pharmacogenetics clinical outcomes study
Millennium Laboratories has commenced clinical outcomes study of its pharmacogenetic test. As part of the study, Millennium will evaluate the relationship between CYP genotype and clinical outcomes that include level of analgesia, functional status...
Clinical Trials
PhaseBio initiates Phase 2b trial of Glymera
PhaseBio Pharmaceuticals has commenced patient dosing in a multicenter Phase 2b trial designed to evaluate the efficacy and safety of three doses of once weekly Glymera compared to matched placebo as well as an active comparator for the...
Clinical Trials
Medistem announces initiation of critical limb ischemia study
Medistem and Shanghai Jia Fu Medical Apparatus have announced the initiation of critical limb ischemia study by treating first two patients with Endometrial Regenerative Cell (ERC) universal donor stem cells. No treatment-associated adverse events...
Clinical Trials
ImmunoGen begins Phase I cancer trial of IMGN853
ImmunoGen has announced the commencement of the Phase I trial of IMGN853 in ovarian cancer and other solid tumours over-expressing its folate receptor target, including non-small cell lung cancer. The multi-centre, first-in-human trial, will...
Clinical Trials
Dyax reports interim analysis data of Phase 2 ecallantide trial
Dyax has reported interim analysis results of Phase 2 trial of ecallantide for acute treatment of angiotensin converting enzyme (ACE) inhibitor-induced angioedema. Based on the data from interim analysis the company decided to discontinue...
Clinical Trials
Quest PharmaTech to start Phase II Oregovomab clinical trial
Quest PharmaTech has got clearance from FDA to initiate US sites for an ongoing international Phase II clinical trial for oregovomab in advanced ovarian cancer patients. The aim of the trial will be to...
Clinical Trials
Bayer, Onyx Phase III NSCLC trial fails to meet primary endpoint
Bayer HealthCare Pharmaceuticals and Onyx Pharmaceuticals have announced that Phase III trial of Nexavar  in non-small cell lung cancer patients did not meet primary endpoint of improving overall survival. The Monotherapy admInistration of Sorafenib...
Subscribe
- Never miss a story with notifications
- Gain full access to our premium content
- Browse free from any location or device.
Must read